Minirin (Desmopressin)

Desmopressin is a selective vasopressin V2 receptor agonist. By binding to V2 receptors in the kidney collecting ducts, it stimulates cAMP production, leading to insertion of aquaporin‑2 channels that reabsorb water, thereby concentrating urine. In haemostatic use, it triggers release of von Willebrand factor and factor VIII from endothelial cells.

The dosage of Minirin is individualized. A qualified prescriber determines the appropriate amount, frequency, and duration based on the specific indication, patient age, weight, renal function and response to therapy.

Safety data for desmopressin in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, and clinicians should weigh potential benefits against risks. Breastfeeding mothers should consult their healthcare provider before using Minirin.

To request Minirin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Desmopressin is a synthetic analogue of vasopressin with higher selectivity for V2 receptors, offering a longer duration of action and fewer vasoconstrictive effects compared with natural vasopressin. This makes it preferable for chronic management of diabetes insipidus and for haemostatic purposes, while other antidiuretics may have broader receptor activity and different side‑effect profiles.

Minirin should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct light to maintain potency throughout the shelf life.

Minirin is supplied as a sublingual tablet. The tablet is placed under the tongue and allowed to dissolve completely without swallowing, ensuring rapid absorption through the oral mucosa. Patients should follow the prescriber’s instructions regarding timing and fluid intake.

The most critical risk is severe hyponatraemia, which can lead to seizures, coma, or even death if water retention is unchecked. Other serious concerns include water intoxication, thrombotic events in patients with elevated clotting factors, and rare allergic reactions such as anaphylaxis.

Minirin is contraindicated in patients with known hypersensitivity to desmopressin, those with uncontrolled hyponatraemia, severe renal impairment, or conditions predisposing to water overload. Caution is also advised for individuals with a history of hyponatraemia‑related seizures.